BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 27752745)

  • 21. (18)F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors.
    Toyonaga T; Hirata K; Yamaguchi S; Hatanaka KC; Yuzawa S; Manabe O; Kobayashi K; Watanabe S; Shiga T; Terasaka S; Kobayashi H; Kuge Y; Tamaki N
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1469-76. PubMed ID: 26841941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of biological parameters in head and neck cancer based on in vivo distribution of
    Cegla P; Kazmierska J; Gwozdz S; Czepczynski R; Malicki J; Cholewinski W
    Tumori; 2020 Feb; 106(1):33-38. PubMed ID: 31446858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.
    Cherk MH; Foo SS; Poon AM; Knight SR; Murone C; Papenfuss AT; Sachinidis JI; Saunder TH; O'Keefe GJ; Scott AM
    J Nucl Med; 2006 Dec; 47(12):1921-6. PubMed ID: 17138734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of hypoxia in human glioblastoma tumors with dynamic 18F-FMISO PET imaging.
    Abdo RA; Lamare F; Fernandez P; Bentourkia M
    Australas Phys Eng Sci Med; 2019 Dec; 42(4):981-993. PubMed ID: 31520369
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Sato J; Kitagawa Y; Watanabe S; Asaka T; Ohga N; Hirata K; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2017 Sep; 124(3):261-270. PubMed ID: 28734696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study.
    Rogasch J; Beck M; Stromberger C; Hofheinz F; Ghadjar P; Wust P; Budach V; Amthauer H; Tinhofer I; Furth C; Walter-Rittel TC; Zschaeck S
    F1000Res; 2020; 9():1350. PubMed ID: 33796277
    [No Abstract]   [Full Text] [Related]  

  • 28. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
    Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
    Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer.
    Rajendran JG; Schwartz DL; O'Sullivan J; Peterson LM; Ng P; Scharnhorst J; Grierson JR; Krohn KA
    Clin Cancer Res; 2006 Sep; 12(18):5435-41. PubMed ID: 17000677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
    Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDG--a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer.
    Zimny M; Gagel B; DiMartino E; Hamacher K; Coenen HH; Westhofen M; Eble M; Buell U; Reinartz P
    Eur J Nucl Med Mol Imaging; 2006 Dec; 33(12):1426-31. PubMed ID: 16841141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT.
    Wang H; Zhang Y; Yu W; Zhao X; Xue Y; Xu H
    Nucl Med Commun; 2016 Jul; 37(7):705-14. PubMed ID: 26963468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Voxel-based analysis of dual-time-point 18F-FDG PET images for brain tumor identification and delineation.
    Prieto E; Martí-Climent JM; Domínguez-Prado I; Garrastachu P; Díez-Valle R; Tejada S; Aristu JJ; Peñuelas I; Arbizu J
    J Nucl Med; 2011 Jun; 52(6):865-72. PubMed ID: 21571807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study.
    Pinker K; Andrzejewski P; Baltzer P; Polanec SH; Sturdza A; Georg D; Helbich TH; Karanikas G; Grimm C; Polterauer S; Poetter R; Wadsak W; Mitterhauser M; Georg P
    PLoS One; 2016; 11(5):e0155333. PubMed ID: 27167829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of the Prognostic Value of Radiomic Features in
    Muzi M; Wolsztynski E; Fink JR; O'Sullivan JN; O'Sullivan F; Krohn KA; Mankoff DA
    Tomography; 2020 Mar; 6(1):14-22. PubMed ID: 32280746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI,
    Collet S; Guillamo JS; Berro DH; Chakhoyan A; Constans JM; Lechapt-Zalcman E; Derlon JM; Hatt M; Visvikis D; Guillouet S; Perrio C; Bernaudin M; Valable S
    J Nucl Med; 2021 Oct; 62(10):1349-1356. PubMed ID: 34016725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O.
    Bruehlmeier M; Roelcke U; Schubiger PA; Ametamey SM
    J Nucl Med; 2004 Nov; 45(11):1851-9. PubMed ID: 15534054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas.
    Szeto MD; Chakraborty G; Hadley J; Rockne R; Muzi M; Alvord EC; Krohn KA; Spence AM; Swanson KR
    Cancer Res; 2009 May; 69(10):4502-9. PubMed ID: 19366800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of hypoxia with 18F-fluoromisonidazole (18F-FMISO) PET/CT in suspected or proven pancreatic cancer.
    Segard T; Robins PD; Yusoff IF; Ee H; Morandeau L; Campbell EM; Francis RJ
    Clin Nucl Med; 2013 Jan; 38(1):1-6. PubMed ID: 23242037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients.
    Thorwarth D; Eschmann SM; Holzner F; Paulsen F; Alber M
    Radiother Oncol; 2006 Aug; 80(2):151-6. PubMed ID: 16920211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.